Wood­ford gets slammed with a bru­tal set of port­fo­lio hits, as North­west con­tin­ues to fes­ter

Neil Wood­ford is find­ing out the hard way just how dif­fi­cult it is to set up a new fund with big in­vest­ments in bio­phar­ma. Af­ter its as­set val­ue plunged about 11%, his sum­ma­ry on H1 2016 notes two un­ex­pect­ed set­backs – key tri­al fail­ures for Cir­cas­sia and Alk­er­mes – along with one self-in­flict­ed wound on North­west Bio­ther­a­peu­tics.

North­west has seen its share price dwin­dle down to a pen­ny stock side show af­ter the com­pa­ny was hit with re­peat­ed al­le­ga­tions of self-deal­ing. Its lead drug pro­gram is al­so ev­i­dent­ly in lim­bo and the biotech’s CEO, Lin­da Pow­ers, even spurned Wood­ford’s sug­ges­tion for a trust­ed in­ves­ti­ga­tor who could do an in­de­pen­dent probe.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER